Forte Biosciences, Inc.
FBRX · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | $0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $21 | $22 | $6 | $14 |
| G&A Expenses | $0 | $11 | $8 | $8 |
| SG&A Expenses | $15 | $11 | $8 | $8 |
| Sales & Mktg Exp. | $0 | -$0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $37 | $32 | $14 | $21 |
| Operating Income | -$37 | -$32 | -$14 | -$21 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $1 | $1 | $0 | -$0 |
| Pre-Tax Income | -$35 | -$31 | -$14 | -$22 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$35 | -$31 | -$14 | -$22 |
| % Margin | – | – | – | – |
| EPS | -12.17 | -24.92 | -19.96 | -38.854 |
| % Growth | 51.2% | -24.8% | 48.6% | – |
| EPS Diluted | -12.17 | -24.92 | -19.96 | -38.854 |
| Weighted Avg Shares Out | 3 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 3 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $1 | $1 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$35 | -$32 | -$14 | -$21 |
| % Margin | – | – | – | – |